Biophore gets DCGI nod to make, export COVID-19 Drug Favipir
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Biophore India Pharmaceuticals has received Drugs Controller General of India licence to manufacture and export Favipiravir, the active pharmaceutical ingredient (API) of an antiviral drug approved by DCGI for use in the treatment of mild to moderate COVID-19 cases.

Announcing the approval, the Hyderabad-based firm said it has successfully completed validation of Favipiravir and scaled-up its production.

Apart from India and Turkey, Favipiravir had been approved for use against Covid-19 in Russia and parts of the Middle East and advanced stage trials were currently underway in other parts of the world.

The company said it was in talks with several Indian partners to commercialise the product in the country and with Bangladesh and Egypt-based companies for its export.

Biophore is also awaiting the DCGI approval for Favipiravir's finished dosage form.

Source: https://www.thehindu.com/sci-tech/health/biophore-india-gets-dcgi-nod-to-manufacture-covid-19-drug-favipiravir/article32076479.ece
Dr. T●●●●z H●●●●●●i and 1 others like this
Like
Comment
Share